Features of hereditary and modifiable risk factors in ovarian cancer of different histotypes
M. Yu. Grafskaya,
A. Yu. Maksimov,
E. V. Verenikina,
A. A. Demidova,
F. V. Logvin,
N. N. Timoshkina,
F. S. Bova https://doi.org/10.33667/2078-5631-2025-26-21-24
Abstract
Purpose of the study. To identify the association between the carriage of BRCA1/2 gene mutations and the histological type of ovarian cancer, as well as morbid obesity as a risk factor.
Materials and methods. The study included 635 patients with epithelial invasive ovarian cancer. The results of histological examination of surgical specimens, height and weight were analyzed. To identify mutations in the BRCA1 and BRCA2 genes, lymphocytes of venous peripheral blood and malignant tumor tissue obtained during surgery were examined. Polymorphisms of the BRCA1 and BRCA2 genes were determined at 8 points using real-time polymerase chain reaction.
Results. Germinal mutations of the BRCA1/2 genes in the blood were detected in 13,5 %. In the subgroups of patients carrying mutations of the BRCA1 and BRCA2 genes, serous ovarian carcinoma was encountered in the predominant number of cases (86,7 and 81,8 % respectively). Genetic analysis of cancer cells from surgical specimens revealed mutations in the BRCA1 and BRCA2 genes in 21,9 %. In 53 women, mutations in the studied genes were detected only in the tumor tissue, but not in the blood, which allowed them to be classified as somatic. The incidence of morbid obesity among patients with spontaneous mutations (20,75 %) is higher (p=0,05) than in women with germline mutations in the BRCA1/2 genes (8,1 %).
Conclusions. Germline mutations in the BRCA1 and BRCA2 genes occur in 13,5 % and are associated with the development of serous ovarian carcinoma. Morbid obesity is a risk factor for spontaneous mutations in repair genes.
About the Authors
M. Yu. Grafskaya
National Medical Research Center of Oncology
Russian Federation
Russian Federation
Grafskaya Maria Yu., PhD Med, doctoral student
Rostov-on-Don
A. Yu. Maksimov
National Medical Research Center of Oncology
Russian Federation
Russian Federation
Maksimov Alexey Yu., DM Sci (habil.), professor, deputy general director
Rostov-on-Don
E. V. Verenikina
National Medical Research Center of Oncology
Russian Federation
Russian Federation
Verenikina Ekaterina V., DM Sci (habil.), head of Dept of Oncogynecology
Rostov-on-Don
A. A. Demidova
Rostov State Medical University
Russian Federation
Russian Federation
Demidova Alexandra A., DM Sci (habil.), associate professor, Head of Dept of Medical Physics, Mathematics and Information Technology
Rostov-on-Don
F. V. Logvin
Rostov State Medical University
Russian Federation
Russian Federation
Logvin Fedor V., PhD Med, associate professor, head of Dept of Epidemiology
Rostov-on-Do
N. N. Timoshkina
National Medical Research Center of Oncology
Russian Federation
Russian Federation
Timoshkina Natalia N., PhD Med, head of the Laboratory of Molecular Oncology
Rostov-on-Don
F. S. Bova
Rostov State Medical University
Russian Federation
Russian Federation
Bova Filipp S., DM Sci (habil.), assistant professor at Dept of Urology and Human Reproductive Health (with a Course in Pediatric Urology-Andrology)
Rostov-on-Don
References
1. Stroganova A. M., Pospekhova N. I., Golovina D. A., Cherepanova I. S., Dranko S. L., Filippova M. G. Review of the results of mass screening for the BRCA1/2 gene mutations in patients with different types of malignant neoplasms. Russian Medical Inquiry. 2022; 6 (6): 297–308 (in Russ.). DOI: 10.32364/2587‑6821‑2022‑6‑6‑297‑308
2. Sokolenko A., Sokolova T., Ni V., Preobrazhenskaya E. V., Iyevleva A. G., Aleksakhina S. N. et al. Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients. Breast Cancer Res Treat. 2020; 184 (1): 229–235. DOI: 10.1007/s10549‑020‑05827‑8
3. Kotsopoulos J., Lubinski J., Gronwald J., Cybulski C., Demsky R., Neuhausen S. L. et al. Hereditary Breast Cancer Clinical Study Group. Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Int J Cancer. 2015 Sep 1; 137(5): 1136–46. DOI: 10.1002/ijc.29386
4. Zhang X., Chiang H., Wang Y., Zhang C., Smith S., Zhao X. et al. Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis. Nat Commun. 2017 Jun 26; 8: 15908. DOI: 10.1038/ncomms15908
5. Maxwell K. N., Wubbenhorst B., Wenz B. M., DeSloover D., Pluta J., Emery L. et al. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nat. Commun. 2017; 8 (1): 1–11. DOI: 10.1038/s41467‑017‑00388‑9
6. Wentzensen N., Poole E. M., Trabert B., White E., Arslan A. A., Patel A. V. et al. Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. J Clin Oncol. 2016 Aug 20; 34 (24): 2888–98. DOI: 10.1200/JCO.2016.66.8178
7. Merritt M. A., Abe S. K., Islam M. R., Rahman M. S., Saito E., Katagiri R. et al. Reproductive factors and risk of epithelial ovarian cancer: results from the Asia Cohort Consortium. Br J Cancer. 2025 Mar; 132 (4): 361–370. DOI: 10.1038/s41416-024-02924-z
8. Gay G. M., Lim J. S., Chay W. Y., Chow K. Y., Tan M. H., Lim W. Y. Reproductive factors, adiposity, breastfeeding and their associations with ovarian cancer in an Asian cohort. Cancer Causes Control. 2015; 26: 1561–73. DOI: 10.1007/s10552‑015‑0649‑6
9. Dedov I. I., Mokrysheva N. G., Melnichenko G. A., Troshina E. A., Mazurina N. V., Ershova E. V. et al. Obesity. Clinical guidelines. Consilium Medicum. 2021; 23 (4): 311–325. (In Russ.). DOI: 10.26442/20751753.2021.4.200832
10. Nagle C. M., Dixon S. C., Jensen A., Kjaer S. K., Modugno F., de Fazio A. et al. Ovarian Cancer Association Consortium. Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. Br J Cancer. 2015; 113 (5): 817–826.
11. Machackova E., Claes K., Mikova M., Házová J., Sťahlová E. H., Vasickova P. et al. Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI – Current Developments for the Classification of Variants. Klin Onkol Summer. 2019; 32 (Sup2): 51–71. DOI: 10.14735/amko2019S 51
12. Snigireva G. P., Rumyantseva V. A., Novikova E. I., Novitskaya N. N., Telysheva E. N., Khazins E. D., Shaikhaev E. G. Algorithm of molecular genetic investigation to identify hereditary BRCA-associated breast cancer. Almanac of Clinical Medicine. 2019; 47 (1): 54–65 (in Russ.). DOI: 10.18786/2072‑0505‑2019‑47002
Review
For citations:
Grafskaya M.Yu., Maksimov A.Yu., Verenikina E.V., Demidova A.A., Logvin F.V., Timoshkina N.N., Bova F.S. Features of hereditary and modifiable risk factors in ovarian cancer of different histotypes. Medical alphabet. 2025;(26):21‑24. (In Russ.) https://doi.org/10.33667/2078-5631-2025-26-21-24
Views:
13
Email this article 